Severe spruelike enteropathy and collagenous colitis caused by olmesartan.
Case report
Collagenous colitis
Intestinal diseases
Spruelike enteropathy
Villous atrophy
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
23 Sep 2021
23 Sep 2021
Historique:
received:
22
05
2021
accepted:
14
09
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Olmesartan, which is an angiotensin II receptor blocker, reportedly causes spruelike enteropathy, with intestinal villous atrophy as its typical histopathological finding. Interestingly, collagenous and/or lymphocytic gastritis and colitis occur in some patients. We report the case of a 73-year-old Japanese man with a 2-month clinical history of severe diarrhea and weight loss. There were few reports in which spruelike enteropathy and collagenous colitis were both observed and could be followed up. We report a case of a 73-year-old man with a 2-month clinical history of severe diarrhea and weight loss. He had taken olmesartan for hypertension treatment for 5 years. Endoscopic examination with biopsies revealed intestinal villous atrophy and collagenous colitis. Suspecting enteropathy caused by olmesartan, which was discontinued on admission because of hypotension, we continued to stop the drug. Within 3 weeks after olmesartan discontinuation, his clinical symptoms improved. After 3 months, follow-up endoscopy showed improvement of villous atrophy but not of the thickened collagen band of the colon. However, the mucosa normalized after 6 months, histologically confirming that the preexistent pathology was finally resolved. This report presents a case in which spruelike enteropathy and collagenous colitis were both observed and could be followed up. In unexplained cases of diarrhea, medication history should be reconfirmed and this disease should be considered a differential diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Olmesartan, which is an angiotensin II receptor blocker, reportedly causes spruelike enteropathy, with intestinal villous atrophy as its typical histopathological finding. Interestingly, collagenous and/or lymphocytic gastritis and colitis occur in some patients. We report the case of a 73-year-old Japanese man with a 2-month clinical history of severe diarrhea and weight loss. There were few reports in which spruelike enteropathy and collagenous colitis were both observed and could be followed up.
CASE PRESENTATION
METHODS
We report a case of a 73-year-old man with a 2-month clinical history of severe diarrhea and weight loss. He had taken olmesartan for hypertension treatment for 5 years. Endoscopic examination with biopsies revealed intestinal villous atrophy and collagenous colitis. Suspecting enteropathy caused by olmesartan, which was discontinued on admission because of hypotension, we continued to stop the drug. Within 3 weeks after olmesartan discontinuation, his clinical symptoms improved. After 3 months, follow-up endoscopy showed improvement of villous atrophy but not of the thickened collagen band of the colon. However, the mucosa normalized after 6 months, histologically confirming that the preexistent pathology was finally resolved.
CONCLUSIONS
CONCLUSIONS
This report presents a case in which spruelike enteropathy and collagenous colitis were both observed and could be followed up. In unexplained cases of diarrhea, medication history should be reconfirmed and this disease should be considered a differential diagnosis.
Identifiants
pubmed: 34556042
doi: 10.1186/s12876-021-01926-y
pii: 10.1186/s12876-021-01926-y
pmc: PMC8461977
doi:
Substances chimiques
Imidazoles
0
Tetrazoles
0
olmesartan
8W1IQP3U10
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350Informations de copyright
© 2021. The Author(s).
Références
Gastrointest Endosc. 2016 Jan;83(1):269-70
pubmed: 26149710
GE Port J Gastroenterol. 2015 Oct 20;23(2):91-95
pubmed: 28868439
Gastroenterology Res. 2020 Aug;13(4):150-154
pubmed: 32864026
Aliment Pharmacol Ther. 2014 Jul;40(1):16-23
pubmed: 24805127
J Gastroenterol Hepatol. 2018 Oct;33(10):1691
pubmed: 29968297
Arch Pathol Lab Med. 2015 Oct;139(10):1242-7
pubmed: 26414468
Am J Gastroenterol. 2007 Aug;102(8):1624-31
pubmed: 17459022
Circulation. 2009 Aug 11;120(6):526-32
pubmed: 19635970
Dig Liver Dis. 2021 Oct;53(10):1262-1267
pubmed: 34330666
Aliment Pharmacol Ther. 2014 Nov;40(9):1103-9
pubmed: 25199794
Intern Med. 2016;55(24):3675-3678
pubmed: 27980272
Mayo Clin Proc. 2018 Apr;93(4):509-517
pubmed: 29622097
Mayo Clin Proc. 2012 Aug;87(8):732-8
pubmed: 22728033
Proc (Bayl Univ Med Cent). 2017 Jul;30(3):348-350
pubmed: 28670083
Scand J Gastroenterol. 2019 Feb;54(2):194-197
pubmed: 30782025
Endoscopy. 2005 Oct;37(10):994-8
pubmed: 16189773
Intern Med. 2021 Jan 15;60(2):217-222
pubmed: 32921688
Dig Endosc. 2014 Jan;26(1):108-12
pubmed: 23368698